Ceftizoxime

Ceftizoxime is a third-generation cephalosporin available for parenteral administration.^[1] Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.

Ceftizoxime

Clinical data
Trade names	Cefizox
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a684043
ATC code	J01DD07 (WHO)
Identifiers
IUPAC name (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number	68401-81-0 68401-82-1
PubChem CID	6533629
ChemSpider	5018818
UNII	C43C467DPE
KEGG	D07658
ChEMBL	ChEMBL528
CompTox Dashboard (EPA)	DTXSID5022772
ECHA InfoCard	100.210.846
Chemical and physical data
Formula	C13H13N5O5S2
Molar mass	383.40 g·mol−1

Synthesis

Injectable third generation cephalosporin antibiotic related to cefotaxime, q.v. Exhibits broad spectrum activity and resistance to β-lactamase hydrolysis.

Ceftizoxime synthesis:^[2][3]